Psoriasis Treatment Market Research Report:
Information by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab,
Infliximab and Etanercept), InterleU.K.in-Inhibitors (Ustekinumab,
SecU.K.inumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol,
Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC)
Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid,
Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-α)
Inhibitors, InterleU.K.in 12 and 23 (IL-12/23) Inhibitors, InterleU.K.in 17
(IL-17) Inhibitor, T cell Inhibitor]} and Region (Americas, Europe,
Asia-Pacific and Middle East & Africa) - Forecast till 2025
Market
Analysis
The Psoriasis
Treatment Market is predicted to touch USD 13.1 billion at a 7.3% CAGR
between 2019-2025, states the latest Market Research Future (MRFR) report.
Psoriasis, simply put, is an autoimmune condition that causes rapid development
of cells on the skin. The overgrowth can result in scaly, thick plaques that
may itch and cause discomfort. Scales generally develop on joints, especially
the knees and elbows, but it may appear in any part of the body including the
face, scalp, neck, feet, and hands.
Various
factors are propelling the global psoriasis treatment market growth. Such
factors, according to the latest Market Research Future report, include
vulnerability towards psoriatic arthritis, favorable reimbursement policies,
growing awareness about psoriasis, increasing availability of biosimilars and
biologics, aging population and changing lifestyle. Additional factors
propelling the growth of the psoriasis treatment market include rising
prevalence of autoimmune diseases, increasing incidence of psoriasis,
increasing R&D activities for psoriasis treatment, and technological
advancements.
On
the contrary, lack of knowledge regarding the exact cause of psoriasis and its
etiology, the high price of medications with their low efficacy and efficiency,
side effects associated with symptomatic treatments, and lack of permanent and
effective treatment are factors that may hamper the psoriasis treatment market
growth during the forecast period.
Market
Segmentation
The
Market Research Future report offers a complete segmental analysis of the
psoriasis treatment market based on treatment type and drug class.
By
drug class, the psoriasis treatment market is segmented into vitamin D
analogues, InterleU.K.in-inhibitors, and tumor necrosis factor inhibitors. The
tumor necrosis factor inhibitors segment is again segmented into etanercept,
infliximab, and adalimumab. The InterleU.K.in-inhibitors segment is again
segmented into brodalumab, ixekizumab, SecU.K.inumab, and ustekinumab. The
vitamin D analogues segment is again segmented into tacalcitol, calcipotriol,
and calcitriol.
By
treatment, the psoriasis treatment market is segmented into biologics,
systematic, and topicals. The topicals segment is again segmented into topical
steroids, topical non-steroids, and over the counter topicals. The systematic
segment is again segmented into methotrexate, cyclosporine, and retinoid. The
biologics segment is again segmented into T cell inhibitor, InterleU.K.in 17
(IL-17) inhibitor, InterleU.K.in 12 and 23 (IL-12/23) inhibitors, and tumor
necrosis factor-alpha (TNF-a) inhibitors.
Browse
Complete Report :https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769
Regional
Analysis
By
region, the psoriasis treatment market report covers the latest trends and
growth opportunities across the Americas, Europe, the Asia Pacific, the Middle
East and Africa, and Latin America. Of these, North America will spearhead the
market during the forecast period. Various factors are propelling the growth of
the psoriasis treatment market in the region, such as the growing awareness
about psoriasis treatment, rising prevalence of psoriasis, presence of key
manufacturers, and increasing health infrastructure.
The
psoriasis treatment market in Europe will have the second-largest share during
the forecast period. Various factors are propelling the growth of the psoriasis
treatment market in the region such as growing awareness about psoriasis, the
launch of biosimilars (amzevita, elerzi), and increasing prevalence of
psoriasis.
The
psoriasis treatment market in the APAC region will grow at the fastest pace
during the forecast period. Various factors are propelling the growth of the
psoriasis treatment market in the region such as growing geriatric population,
large patient pool, improving medical facilities and healthcare infrastructure,
increasing participation of key market players, increasing investments to
develop new therapeutics to treat psoriasis, and increasing awareness.
The
psoriasis treatment market in the MEA will have a small share during the
forecast period for the low economic development in Africa.
The
psoriasis treatment market in Latin America will have a favorable growth during
the forecast period owing to the focus of manufacturers to create novel
therapeutics and rise in the psoriasis patient pool.
Key
Players
Notable
players profiled in the psoriasis treatment market report include Eli Lilly and
Company (US), Amgen (US), AbbVie (US), Merck and Co. Inc (US), Pfizer Inc (US),
Johnson & Johnson (US), Celgene Corporation (US), AstraZeneca (UK), UCB
(Belgium), and Novartis International AG (Switzerland).
Industry
News
Dec
2019: Daavlin, a renowned US-based phototherapy units’ manufacturer that
utilizes therapeutic UV light to effectively and safely treat patients with
eczema, vitiligo, and psoriasis have joined hands with HealthLens to give
patients better access to receive a dermatology consultation as well as
treatment right from their home. The patient just needs to book a consultation
online, followed by uploading some pictures of the skin condition and brief
health history, after which the information will get electronically encrypted
and sent securely to the physician who will respond within 1-2 days.
No comments:
Post a Comment